23.1.2020 13:58:27 CET | ViroGates | Company Announcement

ViroGates A/S
(Nasdaq First North Growth Market Denmark: VIRO), who delivers
blood test
products, primarily for emergency departments in hospitals, today
announces
that it has made a distribution agreement with Interlux Group based
in
Lithuania. The agreement grants Interlux the rights to distribute
ViroGates’
product range in the Baltic region. The Baltic region has approx.
180 hospitals.

Interlux Group is an international company operating from
Vilnius, Lithuania and
with a presence in the medical technology market for
more than 25 years. Along
with subsidiaries it supplies innovative, top-quality
technologies and solutions
for the medicine, science and biotechnology industry
to customers in the Baltic
region. Interlux distributes products from
diagnostic companies such as Becton
Dickinson, DiaSorin, QIAGEN etc. in all the
Baltic states. It has a staff of
more than 100 people.

CEO Jakob Knudsen, says
in a comment: ”ViroGates is pleased to announce this
collaboration with
Interlux Group the leading supplier of diagnostic products in
the Baltic
region. We have been very happy with the insights and relations that
Interlux
have acquired. We have already met with a few hospitals in the Baltic
countries
and they have been very keen to implement our products, and we believe
that
this can be facilitated much stronger by ways of an experienced local
player
such as Interlux.” 

CEO of Interlux Group, Dr. Audrius Matuzevicius says “We
are very happy to have
signed an agreement with ViroGates and looking forward
to the cooperation.
suPARnostic® will from now on be available for the
emergency medicine in the
Baltics and we consider suPARnostic® a very good tool
for supporting the Triage
algorithm at the hospitals. We recently presented
suPAR at the conference of
Laboratory medicine in Vilnius, with a very positive
feedback from the audience.
Interlux see a very interesting potential in suPAR
and are looking forward to
implement it at the hospitals in our region”

 

For
further information contact:

CEO Jakob Knudsen

Tel. (+45) 2226 1355, Email:
jk@virogates.com

ViroGates A/S - www.virogates.com
[http://www.virogates.com]

Interlux
Business Development Director Mr. Ignas
Kamantauskas
Phone: +370 5 278 6850
E-mail: ignas.kamantauskas@interlux.lt

Website: www.interlux.lt [http://www.interlux.lt]

 

Certified
Advisor

Västra Hamnen Corporate Finance

Per Lönn

Tel. (+46) 40 200 250,
Email: per.lonn@vhcorp.se



About ViroGates

ViroGates is an international
medtech company developing and marketing
prognostics products to improve
patient care, reduce healthcare costs and
empower clinical staff in the
healthcare sector. Based on more than 600 clinical
trials and studies,
ViroGates’ suPARnostic® product range supports hospital
professionals in making
clinical decisions on hospitalization or discharge of
acute care patients as
well as detecting and assessing the severity of
cardiovascular diseases, type 2
diabetes, cancer, etc. suPARnostic® TurbiLatex
is available on Siemens ADVIA
XPT instruments and Roche Diagnostics’ cobas
instruments. ViroGates works with
partners to develop solutions for other
platforms. Headquartered in Denmark,
ViroGates’ sales force covers the Nordics,
Germany, Spain, and France, while
distributors serve other markets. 

This message can be found at
https://www.virogates.com/investor/announcements

DISCLAIMER

Prospects about
the future reflect ViroGates' current expectations for future
events and
results. The statements are by nature inherent in risks,
uncertainties and
other matters that are difficult to predict or out of control.
The actual
results may therefore differ from the expectations expressed.

CONTACTS

 *
Jakob Knudsen, CEO, +45 2226 1355, jk@virogates.com 

ATTACHMENTS

 * 20200123
ViroGates Comp. ann 2.pdf
  
[https://via.ritzau.dk/ir-files/13559605/697/714/20200123%20ViroGates%20Comp.
 
 %20ann%202.pdf]